Company Overview and News

6
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position

2018-04-17 seekingalpha
Performance of the Core Biotech Model Account is currently tracking just ahead of the IBB and XBI over the same period of time.

2
Your Daily Pharma Scoop: Intercept's OCA, MediciNova In NASH, Pulse Biosciences Data

2018-04-16 seekingalpha
Intercept Pharmaceuticals (ICPT) reported clinical data from a liver biopsy-based substudy from its phase 3 POISE study. The study indicated that long-term OCA treatment in patients with PBC led to reversal or stabilization of fibrosis and cirrhosis.

 
JF's Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position

2018-04-10 seekingalpha
The rollercoaster ride in the gene therapy space (pessimism due to clinical hold/safety fears followed by optimism over Novartis acquiring AveXis) has been an interesting case study to watch.

2
JF's Core Biotech Buys #9: Shire In Play, Volatility Continues And Capitalizing On Weakness

2018-04-03 seekingalpha
If Takeda successfully bids for Shire (or rival biders come in) it could provide a much-needed boost for the biotech sector.

5
JF's Core Biotech Buys #8: Taking Advantage Of Volatility And Initiating A Position In Dynavax

2018-03-26 seekingalpha
For long term investors weakness and volatility should be seen as an opportunity to add to favorite stocks.

1
Publicatie van het jaarverslag en uitnodiging voor de gewone algemene vergadering

2018-03-23 globenewswire
Mechelen, België; 23 maart 2018, 21.30 CET; gereglementeerde informatie - Galapagos NV (Euronext & NASDAQ: GLPG) heeft haar jaarverslag over boekjaar 2017 gepubliceerd.

1
Galapagos verhoogt kapitaal door uitoefening van warrants

2018-03-20 globenewswire
Mechelen, België; 20 maart 2018, 22.01 CET; gereglementeerde informatie - Galapagos NV (Euronext & NASDAQ: GLPG) kondigt een kapitaalverhoging aan als gevolg van de uitoefening van warrants.

 
Galapagos increases share capital through warrant exercises

2018-03-20 globenewswire
Mechelen, Belgium; 20 March 2018, 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises.

3
JF's Core Biotech Buys Edition 1 Volume 7: Updates And Taking Advantage Of Current Weakness

2018-03-20 seekingalpha
The biotech sector has been a weak performer lately after several bits of bad news came including a clinical hold for Solid Biosciences.

 
Biotech Bio Series #2: Is Gilead Still A Growth Stock?

2018-03-19 seekingalpha
HIV is a bright spot for Gilead but sales growth does not come close to replacing revenue lost from HCV.

 
Tons of garbage cleaned up from Galapagos coast

2018-03-18 technology.inquirer.net
Officials at Ecuador’s Galapagos National Park say they have collected 22 tons of garbage since January off the coasts of the pristine archipelago, some of it from as far away as Asia. Image: Pablo COZZAGLIO – AFP/File

1
JF's Core Biotech Buys Edition 1 Volume 6: Buying Weakness In 2 Beaten Down Stocks

2018-03-12 seekingalpha
Although it's been a very short time, the model account is slightly outperforming the biotech sector at this point.

3
JF's Core Biotech Buys Edition 1 Volume 5: The Importance Of Being Selective

2018-03-06 seekingalpha
I discuss with readers the importance of being selective and having a thick filter when picking stocks.

 
Galapagos' (GLPG) CEO Onno van de Stolpe on Q4 2017 Results - Earnings Call Transcript

2018-02-24 seekingalpha
Hello, everyone. I am Elizabeth Goodwin, Investor Relations and I will be hosting today’s event. This recorded webcast is accessible via the Galapagos website homepage and will be available for replay later on today. So that your questions can be included, we request that you call in to the telephone number given in last night’s press release, that’s 32 for Belgium, 24040659 and the code is 9171161.

 
Galapagos 2017 Q4 - Results - Earnings Call Slides

2018-02-23 seekingalpha
The following slide deck was published by Galapagos in conjunction with their 2017 Q4 earnings call.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...